Nyxoah (NASDAQ:NYXH – Free Report) had its target price trimmed by Stifel Nicolaus from $27.00 to $19.00 in a research report report published on Monday morning, Benzinga reports. The firm currently has a buy rating on the stock.
Several other analysts also recently weighed in on the company. Piper Sandler upped their price objective on Nyxoah from $15.00 to $20.00 and gave the stock an overweight rating in a research report on Wednesday, March 6th. Oppenheimer dropped their price objective on Nyxoah from $20.00 to $15.00 and set an outperform rating for the company in a research report on Wednesday, May 15th. HC Wainwright dropped their price objective on Nyxoah from $22.00 to $18.00 and set a buy rating for the company in a research report on Friday, May 24th. Finally, Cantor Fitzgerald lowered their target price on Nyxoah from $18.00 to $17.00 and set an overweight rating for the company in a report on Wednesday, May 15th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus target price of $17.80.
Check Out Our Latest Report on Nyxoah
Nyxoah Price Performance
Nyxoah (NASDAQ:NYXH – Get Free Report) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.45) earnings per share for the quarter, hitting the consensus estimate of ($0.45). Nyxoah had a negative return on equity of 42.14% and a negative net margin of 843.49%. The business had revenue of $1.33 million during the quarter, compared to the consensus estimate of $1.20 million. As a group, research analysts forecast that Nyxoah will post -1.72 earnings per share for the current year.
Institutional Investors Weigh In On Nyxoah
An institutional investor recently bought a new position in Nyxoah stock. Ikarian Capital LLC purchased a new stake in Nyxoah S.A. (NASDAQ:NYXH – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 50,699 shares of the company’s stock, valued at approximately $684,000.
Nyxoah Company Profile
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.
Recommended Stories
- Five stocks we like better than Nyxoah
- The Role Economic Reports Play in a Successful Investment Strategy
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- How to Evaluate a Stock Before Buying
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- Stock Sentiment Analysis: How it Works
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.